Mr. Hugh MacNaught reports

VENTRIPOINT DOUBLES THE SIZE OF PRIVATE PLACEMENT DUE TO STRONG INVESTOR DEMAND

Ventripoint Diagnostics Ltd. will double its previously announced non-brokered private placement (see news release dated Dec. 30, 2025) from $500,000 to $1-million, subject to TSX Venture Exchange approval.

Each unit will comprise one common share of the corporation and one common share purchase warrant.

Each whole warrant will entitle the holder thereof to purchase one common share at a price of 13 cents for a period of 24 months from the closing of the offering. The corporation reserves the right to accelerate the warrant expiry period upon 30 days of notice, if the common shares trade at 26 cents or above on the TSX-V for a period of 10 consecutive days, including days where no trades occur.

The corporation may pay cash finders' fees and issue common share purchase warrants of up to 8 per cent of the gross proceeds of the offering. Each finder's warrant will be exercisable into one common share at an exercise price of 13 cents per common share for a period of 24 months from the closing of the offering.

The corporation will use the proceeds of the offering to support critical commercialization activities, manufacturing scale-up, continued regulatory submissions and operational requirements.

All securities issued and issuable pursuant to the offering will be subject to a hold period of four months plus one day from the date of closing of the offering. The offering is subject to approval by the exchange.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS+ products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.